DSSG Group: Breast

High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer with an indication of neoadjuvant therapy

To compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients

Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer

To assess the safety and efficacy of pembrolizumab plus the investigator’s choice of chemotherapy compared to placebo plus the investigator’s choice of chemotherapy

with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

to evaluate the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician’s choice

Primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment

This study is a phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA

previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib)

The purpose of this trial is to assess the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis, with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).

HER2-positive primary breast cancer who do not achieve complete response after appropriate neoadjuvant therapy and are at higher risk of disease recurrence.

This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.

either tumor mutation in the BRCA gene HER2- breast cancer (independent of hormone receptor status, including HR-positive and TNBC) or tumor BRCA wild type triple-negative breast cancer (TNBC)

To assess the efficacy and safety of Niraparib in participants with the molecular disease based on the presence of circulating tumor Deoxyribonucleic acid (ctDNA) following surgery or completion of adjuvant therapy. Participants who have completed definitive therapy at any time in the past are eligible for ctDNA monitoring and potential enrollment onto the trial.

breast cancer patients undergoing a mastectomy

To investigate the use of the two cutting and sealing devices currently used in mastectomy, LigaSure™ versus monopolar diathermy. At this time, the device that is utilised is the surgeons own preference.

Early stage breast cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab.

Breast cancer

The purpose of this trial is to examine the function of different genes and proteins, previously identified to be of interest, and identify new ones, as well as the means by which they interact and differ between cancer cells.